Arthneeti
Sigachi Indust.Q2 FY24

Sigachi Indust. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹37.9P/E: 64.5Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Sigachi Industries targets at least 25% year-on-year top line growth over the next 3 to 5 years, primarily driven by the pharma vertical.
  • Continued investments are planned in capacities, related product lines, and facilities to support growth.
  • Complementary verticals like food & nutrition are expected to grow and contribute to revenue.
  • New joint ventures, including with international partners, are anticipated to add business and revenue.
  • Sales from expanded capacities, especially in MCC and CCS, are expected to start reflecting by Q4 FY24.
  • The recently acquired API unit aims for Rs. 60 crores revenue in the current financial year with integration progressing.
  • Expansion in the Middle East (MENA region) through joint ventures is seen as a substantial growth opportunity.
  • The company is focused on increasing volumes and customer base globally with exports to over 60 countries.

See what Sigachi Indust. management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript does not mention any specific current or future plans for fundraising through debt or equity.
  • The management primarily discusses ongoing and planned capital expenditures (CapEx) for capacity expansion and modernization, particularly in MCC plants, CCS projects, and API facilities.
  • CapEx is being funded as planned, with no explicit mention of raising external capital via debt or equity.
  • The company is focusing on stabilizing current operations before commencing further expansions.
  • There is an emphasis on achieving organic growth, joint ventures, and capacity enhancements rather than external fundraising.
  • If any fundraising plans exist, they have not been disclosed in this earnings call.

See what Sigachi Indust. management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Ongoing CapEx to enhance manufacturing capacity from 13,800 to approximately 21,000 MTPA across Gujarat and Telangana facilities.
  • Expansion of MCC plant commissioning expected by end of Q3 FY24, with sales starting Q4 FY24.
  • CCS project awaiting environmental clearance expected by December 2023; civil works to commence immediately post-clearance.
  • Brownfield expansion at the Hyderabad plant to continue gradually without affecting current production.
  • API subsidiary capacity expansion CapEx planned but not yet started; expected to commence in about 3 months.
  • Joint ventures signed recently, including one in Saudi Arabia (MENA region) to establish local manufacturing and boost regional growth.
  • Emphasis on investing in related product lines and facilities to target at least 25% top-line growth over next 3-5 years.
  • Focus on regulatory certifications (European Directorate, US FDA) for API business to improve margins and market reach.

Track Sigachi Indust. — get its next earnings analysis in your feed

Margin guidance

Category 1
  • Sigachi Industries targets at least 25% year-on-year top line growth over the next 3 to 5 years, driven mainly by the pharma vertical and complementary segments like food & nutrition.
  • Anticipate margin improvement in the API space post regulatory certifications and audits, positively impacting overall margins.
  • EBITDA margins expected to be comfortably above 20%.
  • Earnings growth supported by ongoing expansion in capacities and new product lines, including joint ventures with international firms.
  • The company is optimistic about achieving Rs. 400 crores revenue guidance for FY24, with increasing contributions from API and expanded MCC capacities.
  • Profitability expected to improve in coming quarters due to better product mix, cost-effective manufacturing, and inventory management.
  • Employee costs may rise initially due to acquisitions but expected to stabilize with increased sales, supporting EPS growth over time.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Sigachi Industries Limited. However, related insights include: - Sigachi is continuously working on expanding capacities, including MCC and CCS plants, with commissioning expected by Q4 FY24, indicating ongoing and upcoming orders. - The company is targeting a 25% top-line growth year-on-year over the next 3 to 5 years, showing a positive sales outlook. - Recent acquisitions and joint ventures, including the API manufacturing unit (Trimax Biosciences) and international partnerships, suggest an expanding order pipeline. - Management expressed confidence in meeting revenue targets, such as Rs. 400 crores for FY24, supported by increased sales from existing and new capacities. - The company exports to over 60 countries, implying steady export order inflow. If you seek specific orderbook figures, these were not detailed in the call transcript.

How does Sigachi Indust. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSigachi Indust.
Rev 2Mar 1
See where Sigachi Indust. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Sigachi Indust. rank in Pharmaceuticals & Biotechnology?

Compare Sigachi Indust. against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What Sigachi Indust.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →